In First, Aging Stopped in Humans: TAU Co-Study

Written on |

New research finds that high pressure treatments can reverse two processes associated with aging and its illnesses

A first-of-its-kind clinical trial in human subjects: A new study from Tel Aviv University and the Shamir Medical Center indicates that HBOT (treatments with high-pressure oxygen) in healthy aging adults can stop the aging of blood cells.

The researchers found that a unique protocol of treatments in a pressure chamber can reverse two major processes associated with aging and its illnesses: the shortening of telomeres – protective regions located at both ends of every chromosome (the chromosomes contain the genetic material in the cell’s nucleus), and the accumulation of senescent (old and malfunctioning) cells in the body. Focusing on immune cells containing DNA, obtained from the participants’ blood, the study discovered a significant lengthening – up to 38% – of the telomeres, as well as a decrease of up to 37% in the presence of senescent cells.

The study was led by Prof. Shai Efrati, faculty member of the Sackler School of Medicine and the Sagol School of Neuroscience at Tel Aviv University and Founder and Director of the Sagol Center of Hyperbaric Medicine at the Shamir Medical Center, and Dr. Amir Hadanny, Chief Medical Research Officer of the Sagol Center for Hyperbaric Medicine and Research at the Shamir Medical Center. The clinical trial was conducted as part of a comprehensive Israeli research program that targets aging as a reversible disease. The paper was published in the scientific journal Aging in November 2020.

Prof. Efrati explains:  “For many years our team has been engaged in hyperbaric research and therapy – treatments based on protocols of exposure to high-pressure oxygen at various concentrations inside a pressure chamber. Our achievements over the years included the improvement of brain functions damaged by age, stroke or brain injury. In the current study we wished to examine the impact of HBOT on healthy and independent aging adults, and to discover whether such treatments can slow down, stop or even reverse the normal aging process at the cellular level.”

The researchers exposed 35 healthy individuals aged 64 or over to a series of 60 hyperbaric sessions over a period of 90 days. Each participant provided blood samples at four different points in time – before, during, at the end and after the series of treatments, and the researchers analyzed various immune cells (cells containing DNA) in the blood and compared the results.

The findings indicated that the treatments actually reversed the aging process in two of its major aspects: The telomeres at the ends of the chromosomes grew longer instead of shorter, at a rate of 20%-38% for the different cell types; and the percentage of senescent cells in the overall cell population was reduced significantly – by 11%-37% depending on cell type.

Prof. Efrati: “Today telomere shortening is considered the ‘Holy Grail’ of the biology of aging. Researchers around the world are trying to develop pharmacological and environmental interventions that enable telomere elongation.  Our HBOT protocol was able to achieve this, proving that the aging process can in fact be reversed at the basic cellular-molecular level.”

Dr. Hadanny: “Until now, interventions such as lifestyle modifications and intense exercise were shown to have some inhibiting effect on telomere shortening. But in our study, only three months of HBOT were able to elongate telomeres at rates far beyond any currently available interventions or lifestyle modifications. With this pioneering study, we have opened a door for further research on the cellular impact of HBOT and its potential for reversing the aging process.”

Related posts

Hyperbaric Treatment More Effective than Medicines for Fibromyalgia Caused by Head Injury

24 March 2023

Promoting Women in Medicine

9 March 2023

#TAU_WOMEN_POWER

7 March 2023

Researchers Discover Mechanism that Facilitates Formation of Brain Metastases

27 February 2023

Light Pollution is Killing Desert Rodents

10 February 2023

Three Tel Aviv University Researchers Awarded the ERC Proof of Concept (PoC) grants

9 February 2023

Researchers Identify A New Genetic Risk Factor for Age-related Eye Disease

8 February 2023

People With Autism Experience Pain at a Higher Intensity

31 January 2023

Researchers Uncover New Factors Linked to Williams Syndrome

24 January 2023

Lessons in Tolerance and DNA Extraction in Tel Aviv University’s Medical Labs

18 January 2023

Medical Clowns – No Laughing Matter

18 January 2023

Tel Aviv University’s First MedTech Hackathon Sets a High Bar

15 January 2023

Researchers use Smartwatches to Measure Safety of COVID Vaccine

28 December 2022

Tel Aviv University Establishes Multidisciplinary Center for Research of Autoimmune Diseases

18 December 2022

Breakthrough in the Field of Controlled Drug Delivery

16 December 2022

Common Medications May Reduce Risk of Metastases after Colon and Rectal Cancer

9 December 2022

Victoria

Tok Corporate Centre, Level 1,
459 Toorak Road, Toorak VIC 3142
Phone: +61 3 9296 2065
Email: office@aftau.asn.au

New South Wales

Level 22, Westfield Tower 2, 101 Grafton Street, Bondi Junction NSW 2022
Phone: +61 418 465 556
Email: davidsolomon@aftau.org.au

Western Australia

P O Box 36, Claremont,
WA  6010
Phone: :+61 411 223 550
Email: clivedonner@thelinqgroup.com